Skip to main content
    P

    Pharming Group NV (PHAR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $12.59
    -0.01 (-0.08%)

    Market Cap: $891.80M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Pharming Group NV (PHAR) Earnings: Report Dates and Results

    Updated Oct 27, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    In the quarter ended Sep 30, 2026, Pharming Group NV reported EPS of $0.30, below the $0.33 estimate. It beat the EPS estimate in 3 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    28%(8/29)
    Avg Surprise
    -75.03%

    Upcoming Estimates

    Report date not yet scheduledPeriod ending Dec 31, 2026
    EPS Consensus$0.02
    Range$0.02 - $0.03
    5 analysts
    Revenue Consensus
    $116.62M
    Range$110.96M - $118.88M
    5 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS Consensus-$0.01
    Range-$0.01 - -$0.01
    1 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$0.00n/a
    60d ago$0.00n/a
    30d ago$0.00n/a
    7d ago$0.00n/a
    Current-$0.01
    Revenue Consensus
    $77.00M
    Range$77.00M - $77.00M
    1 analysts

    Next Report

    Analysts' consensus for the quarter ending Dec 31, 2026 is 71.4% below the $0.07 reported for the quarter ended Dec 31, 2025.

    PHAR's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.

    PHAR Earnings Call

    The latest PHAR earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 29 quarters below that had an estimate, PHAR beat 8, missed 19 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $117.56M, up 20.8% from $97.29M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.30$0.33$0.02 - $0.39-9.09%Miss+2900.0%20 up, 0 downOct 27, 2026$117.56M
    Jun 30, 2026$0.02$0.20N/A-90.00%Miss+100.0%30 up, 0 downJul 30, 2026$90.21M
    Mar 31, 2026-$0.07$0.01-$0.01 - $0.01-800.00%MissN/A30 up, 0 downMay 7, 2026$72.45M
    Dec 31, 2025$0.07$0.01$0.01 - $0.02+498.29%Beat+1300.0%20 up, 1 downMar 12, 2026$106.50M
    Sep 30, 2025$0.01-$0.13N/A+108.00%BeatN/A20 up, 0 downNov 6, 2025$97.29M
    Jun 30, 2025$0.01-$0.01-$0.03 - $0.00+200.00%BeatN/A20 up, 0 downJul 31, 2025$93.22M
    Mar 31, 2025-$0.02-$0.02-$0.03 - -$0.020.00%In lineN/A20 up, 0 downMay 8, 2025$79.09M
    Dec 31, 2024$0.01$0.01$0.01 - $0.01-41.18%MissN/A20 up, 1 downMar 13, 2025$92.70B
    Sep 30, 2024-$0.02$0.00N/A-512.00%Miss-253.0%N/AN/AOct 24, 2024$74.85M
    Jun 30, 2024-$0.02$0.00N/A-785.00%Miss-277.0%N/AN/AAug 1, 2024$74.09M
    Mar 31, 2024-$0.02$0.01N/A-300.00%MissN/AN/AN/AMay 8, 2024$55.59M
    Dec 31, 2023-$0.04$0.00N/AN/AN/AN/AN/AN/AMar 14, 2024$81.87M
    Sep 30, 2023$0.01-$0.01N/A+200.00%Beat0.0%N/AN/AOct 26, 2023$66.66M
    Jun 30, 2023$0.01-$0.02N/A+150.00%Beat0.0%N/AN/AAug 3, 2023$54.90M
    Mar 31, 2023-$0.02-$0.17N/A+88.24%Beat-300.0%N/AN/AMay 11, 2023$42.54M
    Dec 31, 2022-$0.21-$0.21N/A+2.38%Beat-1466.7%N/AN/AMar 16, 2023$54.62M
    Sep 30, 2022$0.01$0.40N/A-97.50%MissN/AN/AN/AOct 27, 2022$54.24M
    Jun 30, 2022$0.01$0.01N/A0.00%In line-80.9%N/AN/AAug 4, 2022$50.15M
    Mar 31, 2022$0.01$0.05N/A-80.00%Miss-93.6%N/AN/AMay 12, 2022$46.62M
    Dec 31, 2021$0.02$0.02N/A-25.00%Miss-86.9%N/AN/AMar 17, 2022$45.75M
    Sep 30, 2021$0.00$0.04N/A-101.21%Miss-103.8%N/AN/AOct 28, 2021$49.44M
    Jun 30, 2021$0.05$0.10N/A-47.60%Miss+347.9%N/AN/AAug 9, 2021$49.74M
    Mar 31, 2021$0.16$0.16N/A-1.88%Miss+887.4%N/AN/AApr 7, 2021$43.56M
    Dec 31, 2020$0.11$0.11N/A+4.00%Beat+845.5%N/AN/AMar 30, 2021N/A
    Sep 30, 2020$0.01$0.12N/A-89.00%Miss-35.0%N/AN/AOct 29, 2020$58.52M
    Jun 30, 2020$0.01$0.15N/A-92.20%Miss-32.4%N/AN/AJul 30, 2020$45.27M
    Mar 31, 2020$0.02$0.12N/A-86.75%Miss+39.5%N/AN/AJun 29, 2020$54.37M
    Dec 31, 2019$0.01$0.20N/A-93.95%Miss+8.0%N/AN/AMar 30, 2020$54.37M
    Sep 30, 2019$0.02$0.18N/A-88.72%Miss-22.2%N/AN/AOct 24, 2019$46.35M
    Jun 30, 2019$0.02$0.12N/A-85.58%Miss+106.0%N/AN/AJul 26, 2019$49.06M
    Mar 31, 2019$0.01N/AN/AN/AN/A+100.0%N/AN/AJun 29, 2019$39.56M
    Dec 31, 2018$0.01N/AN/AN/AN/A+13.1%N/AN/AMar 30, 2019$40.37M
    Sep 30, 2018$0.03N/AN/AN/AN/AN/AN/AN/ADec 31, 2018$45.46M
    Jun 30, 2018$0.01N/AN/AN/AN/AN/AN/AN/ASep 30, 2018$32.39M
    Mar 31, 2018$0.01N/AN/AN/AN/AN/AN/AN/AJun 29, 2018$36.35M
    Dec 31, 2017$0.01N/AN/AN/AN/AN/AN/AN/AMar 30, 2018$40.91M
    Sep 30, 2017-$0.09N/AN/AN/AN/AN/AN/AN/ADec 31, 2017$31.55M
    Jun 30, 2017-$0.02N/AN/AN/AN/AN/AN/AN/ASep 30, 2017$18.54M
    Mar 31, 2017-$0.06N/AN/AN/AN/AN/AN/AN/AJun 29, 2017$16.52M
    Dec 31, 2016-$0.01N/AN/AN/AN/AN/AN/AN/AMar 30, 2017$6.94M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $0.07, a profit after a loss of $0.05 per share the year before. It was -$0.05 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$0.07N/A
    Dec 31, 2024-$0.05N/A
    Dec 31, 2023-$0.04N/A
    Dec 31, 2022-$0.18-178.2%
    Dec 31, 2021$0.22+44.3%
    Dec 31, 2020$0.16+154.0%
    Dec 31, 2019$0.06N/A
    Dec 31, 2018$0.05N/A
    Dec 31, 2017-$0.15N/A
    Dec 31, 2016-$0.05N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,900 words across 9 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20265,9189
    2026Q2Jun 30, 20266,52211
    2026Q1Mar 31, 20266,49712
    2025Q3Sep 30, 20255,06910
    2025Q2Jun 30, 20255,0418
    2025Q1Mar 31, 20255,5319
    2024Q4Dec 31, 20246,03410
    2024Q3Sep 30, 20242,6878

    2026Q3 Earnings Call

    Opening remarks

    Kenneth Lynard Interim Co-CEO Thank you, operator. Good morning and good afternoon, everyone, and thank you for joining Pharming's third-quarter 2026 call. I am joined today by Leverne Marsh, my fellow interim co-CEO and our chief commercial officer, and Dr. Anurag Relan, our chief medical officer. After my opening remarks, Leverne will review our commercial performance, Anurag will cover R&D, and I will return to take you through the financials and outlook before we open the line for questions. As you know, on September 29, Fabrice Chouraqui stepped down as CEO, and the board appointed Leverne and me as interim co-CEOs while it conducts a formal search for a permanent successor. As of now, there are no additional updates to report. Despite these changes, our strategy, pipeline, and commitment to patients remain unchanged. Before we begin, please note that we will be making forward-looking statements on this call. These are based on our current expectations and plans, and actual results may differ materially. Please refer to the full statement on this slide. We are pleased to report a strong third-quarter performance. Before I go further, I want to comment on why we decided to report results today rather than on November 5, as originally scheduled. Because our third-quarter results came in above analyst consensus, we issued a pre-release on October 22 with top-line revenues and operating expenses only. We appreciated that, once these numbers were public, investors would want to see the full details behind them as soon as possible and have the opportunity to ask questions. As a result, we moved up the date for our full third-quarter disclosure to today. The change in date is not related to any transaction or restructuring of the company. Getting back to this slide, as many of you who have followed Pharming know, our strategy rests on three pillars. RUCONEST continues to provide a durable source of cash flow, and I am pleased to report it has returned to growth this quarter. Joenja, a high-growth asset still early in its life cycle, is expanding geographically and with a new pediatric indication. And we have a high-value clinical pipeline with two potential billion-dollar opportunities: leniolisib in broader primary immunodeficiencies, including CVID, and nepasimone in mitochondrial DNA-driven primary mitochondrial disease. Turning to the quarter in more detail, total revenue grew 21% to $117.6 million, ahead of market expectations. This quarter, RUCONEST returned to revenue growth, Joenja sales grew 58%, and our operating profit increased by 89%. We are also tightening our full-year revenue guidance to $380 million to $390 million and lowering our operating expense guidance to $310 million to $315 million. Both of our commercial products contributed to growth.

    Frequently Asked Questions About PHAR

    Did PHAR beat earnings estimates last quarter?

    No. Pharming Group NV reported EPS of $0.30 for the quarter ended Sep 30, 2026, below the $0.33 estimate by 9.09%.

    What EPS do analysts expect from PHAR next quarter?

    The consensus EPS estimate for Pharming Group NV for the quarter ending Dec 31, 2026 is $0.02 from 5 analysts, with estimates from $0.02 to $0.03.

    How often does PHAR beat earnings estimates?

    Pharming Group NV beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -16.75%.